Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female~* Documented diagnosis of pyuria~* Documented diagnosis of cUTI or Acute Pyelonephritis (AP)~Exclusion Criteria:~* Receipt of effective antibacterial drug therapy for cUTI for more than 24 hours during the previous 72 hours prior to randomization~* A urine culture result is resistant to meropenem or a gram negative pathogen is not identified or more than 2 microorganisms are isolated or a confirmed fungal UTI is identified~* Required use of nonstudy systemic bacterial therapy~* Suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually transmitted disease~* Patients with perinephric or renal abscess~* Patients with renal transplantation or receiving hemodialysis or peritoneal dialysis~* Abnormal labs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cefepime/VNRX-5133 (taniborbactam) (Type: EXPERIMENTAL): Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
- Meropenem (Type: ACTIVE_COMPARATOR): Meropenem will be administered q8h IV over 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).